Cardiol Therapeutics Expands Phase III MAVERIC Trial Network, Reaches 75% Patient Enrollment

summarizeSummary

Cardiol Therapeutics announced significant progress in its pivotal Phase III MAVERIC trial, expanding its U.S. clinical network and achieving 75% patient enrollment for its recurrent pericarditis therapy, CardiolRx™.

check_boxKey Events

• Phase III Trial Network Expanded

  Cardiol Therapeutics is expanding its U.S. MAVERIC Phase III trial network by activating up to seven additional clinical centers, bringing the total number of sites to an anticipated 25. This expansion reflects strong interest from leading institutions like Cleveland Clinic, Mayo Clinic, and Massachusetts General Hospital.

• Patient Enrollment Reaches 75%

  Patient enrollment in the pivotal MAVERIC trial has reached 75%, a significant increase from over 50% reported in early January. The trial is designed to enroll approximately 110 patients.

• Target Recruitment Timeline Updated

  Target recruitment is now anticipated by the end of Q2 2026, with the potential to extend into Q3 to accommodate patient enrollment from the newly added clinical sites.

• Pivotal Trial for NDA Submission

  The MAVERIC trial is a randomized, double-blind, placebo-controlled pivotal Phase III study evaluating CardiolRx™ for recurrent pericarditis, and its successful completion is expected to support a New Drug Application (NDA) with the U.S. FDA.

auto_awesomeAnalysis

This filing provides a significant positive update on Cardiol Therapeutics' pivotal Phase III MAVERIC trial for recurrent pericarditis. Expanding the clinical site network to include leading institutions and achieving 75% patient enrollment are critical de-risking milestones for a late-stage life sciences company. The strong interest from clinical centers underscores the perceived unmet need and therapeutic potential of CardiolRx™. Successful completion of this trial is expected to support a New Drug Application with the U.S. FDA, targeting a substantial market of approximately 40,000 patients annually in the U.S. While recruitment may extend slightly into Q3, the overall progress and increased site participation are strong indicators of the program's advancement.